Key Points
- This month, Profound Medical announced major distribution agreements that expand its reach to Australia, New Zealand, Saudi Arabia, and Canada.
- Profound has two therapeutic ultrasound devices on the market – the TULSA-PRO and the Sonalleve.
This month, Profound Medical announced three exclusive distribution agreements to expand its global reach.
Profound Medical is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound, and closed-loop temperature feedback control to treat patients with prostate diseases like cancer and benign prostatic hyperplasia. The company is also marketing Sonalleve®, an innovative therapeutic platform for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors, and osteoid osteoma.
In its press releases, the company states, “As user interest in Profound’s technologies continues to build, the company is deploying its own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world.”
Read the press releases below to learn about Profound’s to expand to Australia, New Zealand, and Saudi Arabia, as well as to continue a longstanding partnership in Canada.
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
Profound has established an exclusive distribution and supply agreement for its TULSA-PRO® system with Getz Healthcare, a leading distributor of medical devices, equipment and consumables in Australia and New Zealand. The company is also eyeing additional opportunities to expand in key markets across Asia Pacific.
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Profound has signed an exclusive distribution and supply agreement for its TULSA-PRO® and Sonalleve® technologies in Saudi Arabia with Al Faisaliah Medical Systems Co. This agreement will enable the company to penetrate the largest healthcare market in the Middle East, and all required regulatory approvals to import and sell Profound’s two advanced ablative technologies in Saudi Arabia are already in place.
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
Profound will continue an exclusive distribution rights agreement that began in April 2015 that enables Knight Therapeutics Inc. to distribute the TULSA-PRO® device in Canada.